Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CFLAR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CFLAR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CFLAR_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CFLAR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CFLAR_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CFLAR_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CFLAR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005138420 | Esophagus | ESCC | response to glucocorticoid | 85/8552 | 148/18723 | 2.60e-03 | 1.11e-02 | 85 |
GO:19038447 | Esophagus | ESCC | regulation of cellular response to transforming growth factor beta stimulus | 76/8552 | 131/18723 | 2.96e-03 | 1.24e-02 | 76 |
GO:20003783 | Esophagus | ESCC | negative regulation of reactive oxygen species metabolic process | 34/8552 | 52/18723 | 3.26e-03 | 1.35e-02 | 34 |
GO:006053716 | Esophagus | ESCC | muscle tissue development | 211/8552 | 403/18723 | 3.84e-03 | 1.56e-02 | 211 |
GO:00972847 | Esophagus | ESCC | hepatocyte apoptotic process | 13/8552 | 16/18723 | 4.05e-03 | 1.62e-02 | 13 |
GO:00702654 | Esophagus | ESCC | necrotic cell death | 39/8552 | 62/18723 | 4.68e-03 | 1.82e-02 | 39 |
GO:00330025 | Esophagus | ESCC | muscle cell proliferation | 134/8552 | 248/18723 | 4.80e-03 | 1.86e-02 | 134 |
GO:003103219 | Esophagus | ESCC | actomyosin structure organization | 108/8552 | 196/18723 | 4.86e-03 | 1.88e-02 | 108 |
GO:00109764 | Esophagus | ESCC | positive regulation of neuron projection development | 91/8552 | 163/18723 | 5.72e-03 | 2.13e-02 | 91 |
GO:00715487 | Esophagus | ESCC | response to dexamethasone | 26/8552 | 39/18723 | 6.63e-03 | 2.43e-02 | 26 |
GO:00016559 | Esophagus | ESCC | urogenital system development | 177/8552 | 338/18723 | 7.51e-03 | 2.69e-02 | 177 |
GO:19040197 | Esophagus | ESCC | epithelial cell apoptotic process | 68/8552 | 121/18723 | 1.27e-02 | 4.21e-02 | 68 |
GO:00713849 | Esophagus | ESCC | cellular response to corticosteroid stimulus | 37/8552 | 61/18723 | 1.32e-02 | 4.31e-02 | 37 |
GO:19030532 | Esophagus | ESCC | regulation of extracellular matrix organization | 30/8552 | 48/18723 | 1.40e-02 | 4.57e-02 | 30 |
GO:001470615 | Esophagus | ESCC | striated muscle tissue development | 197/8552 | 384/18723 | 1.46e-02 | 4.74e-02 | 197 |
GO:00485457 | Liver | NAFLD | response to steroid hormone | 75/1882 | 339/18723 | 3.44e-11 | 1.12e-08 | 75 |
GO:00713755 | Liver | NAFLD | cellular response to peptide hormone stimulus | 65/1882 | 290/18723 | 3.95e-10 | 9.62e-08 | 65 |
GO:00420607 | Liver | NAFLD | wound healing | 84/1882 | 422/18723 | 6.56e-10 | 1.37e-07 | 84 |
GO:00713836 | Liver | NAFLD | cellular response to steroid hormone stimulus | 48/1882 | 204/18723 | 1.50e-08 | 1.83e-06 | 48 |
GO:19016536 | Liver | NAFLD | cellular response to peptide | 71/1882 | 359/18723 | 1.82e-08 | 2.09e-06 | 71 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CFLAR | SNV | Missense_Mutation | | c.670N>A | p.Val224Met | p.V224M | O15519 | protein_coding | deleterious(0.04) | possibly_damaging(0.798) | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CFLAR | SNV | Missense_Mutation | novel | c.1152N>C | p.Glu384Asp | p.E384D | O15519 | protein_coding | tolerated(0.56) | benign(0.003) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CFLAR | SNV | Missense_Mutation | novel | c.565G>T | p.Ala189Ser | p.A189S | O15519 | protein_coding | tolerated(1) | benign(0) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CFLAR | insertion | In_Frame_Ins | novel | c.1150_1151insTTTTCCCCAGAGCTTCTTCGAGACACCTTC | p.Glu384delinsValPheProArgAlaSerSerArgHisLeuGln | p.E384delinsVFPRASSRHLQ | O15519 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CFLAR | insertion | Nonsense_Mutation | novel | c.700_701insCACTGTAGCCAGACTGCCTCTCTAGA | p.Phe234SerfsTer3 | p.F234Sfs*3 | O15519 | protein_coding | | | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
CFLAR | SNV | Missense_Mutation | | c.1143G>T | p.Lys381Asn | p.K381N | O15519 | protein_coding | tolerated(0.4) | benign(0.015) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CFLAR | SNV | Missense_Mutation | | c.877N>A | p.Leu293Ile | p.L293I | O15519 | protein_coding | tolerated(0.08) | possibly_damaging(0.906) | TCGA-AA-A01Z-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CFLAR | SNV | Missense_Mutation | novel | c.803N>A | p.Arg268Gln | p.R268Q | O15519 | protein_coding | tolerated(0.36) | benign(0.003) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
CFLAR | SNV | Missense_Mutation | | c.653N>A | p.Gly218Asp | p.G218D | O15519 | protein_coding | tolerated(0.56) | benign(0) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CFLAR | SNV | Missense_Mutation | novel | c.191N>A | p.Arg64Gln | p.R64Q | O15519 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | BAY-11-7085 | BAY-11-7085 | 22326395 |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | DEHYDROEQUOL | IDRONOXIL | |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | FINASTERIDE | FINASTERIDE | 11399535 |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | BICALUTAMIDE | BICALUTAMIDE | 22623731 |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | NINTEDANIB | NINTEDANIB | |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | CABOZANTINIB | CABOZANTINIB | |
8837 | CFLAR | DRUG RESISTANCE, DRUGGABLE GENOME, PROTEASE | | DOVITINIB | DOVITINIB | |